Eli Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program
TX-478 could potentially address 30-40 per cent of people with hormone-positive breast cancer, building on Lilly's advancements…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.